An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26, 2021. Merck & Co Inc/Handout via REUTERS
Dec 3 (Reuters) – Merck & Co (MRK.N) said on Friday it would supply Canada with up to 1 million courses of molnupiravir, its experimental oral antiviral medicine for the treatment of COVID-19.
The government of Canada has secured access to 500,000 courses in 2022, with options for up to 500,000 more, pending Health Canada's approval, the company said.
Merck said it had filed the final molnupiravir real-time application seeking approval in Canada last month.
Rival Pfizer Inc (PFE.N) said on Wednesday it had started the real-time submission of an application seeking Health Canada's approval of its oral COVID-19 antiviral drug candidate. read more
Canada's government earlier this week said it was in advanced talks with Pfizer and Merck regarding a purchase agreement for COVID-19 antiviral drugs as the country prepares to curb the spread of the new Omicron variant of the coronavirus. The country has so far discovered a total of 11 cases of the variant. read more
Merck said it expects to produce 10 million courses of treatment by the end of 2021, with at least 20 million courses to be produced in 2022.
Merck also entered into a pact with the U.S. Government to supply about 3.1 million courses of molnupiravir, upon Emergency Use Authorization (EUA) or approval from the country's health regulator.
Our Standards: The Thomson Reuters Trust Principles.
Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2021 Reuters. All rights reserved
